Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (7030)
All Articles published online
|
Publishing Process of This Article
|
Aug 14, 2020 (publication date) through Apr 25, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441 [PMID: 32874055 DOI: 10.3748/wjg.v26.i30.4428] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm |
| Number | Citing Articles |
| 1 |
Hu Zhang, Chenlu Mu, Yu Gu, Fanyi Meng, Xiali Qin, Hailong Cao. Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis. Pharmacological Research 2024; 202: 107108 doi: 10.1016/j.phrs.2024.107108
|
| 2 |
Daisuke Saito, Minoru Matsuura, Ryo Ozaki, Sotaro Tokunaga, Shintaro Minowa, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Mari Hayashida, Jun Miyoshi, Tadakazu Hisamatsu. Clinical response of vedolizumab at week 6 predicted endoscopic remission at week 24 in ulcerative colitis. JGH Open 2021; 5(9): 1056 doi: 10.1002/jgh3.12630
|
| 3 |
Javier P. Gisbert, María Chaparro. Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?. Journal of Clinical Medicine 2021; 10(22): 5318 doi: 10.3390/jcm10225318
|
| 4 |
|
| 5 |
Carl Eriksson, Sara Rundquist, Vyron Lykiardopoulos, Ruzan Udumyan, Per Karlén, Olof Grip, Charlotte Söderman, Sven Almer, Erik Hertervig, Jan Marsal, Jenny Gunnarsson, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjöberg, David Öberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson. Real-world effectiveness of vedolizumab in inflammatory bowel disease: week 52 results from the Swedish prospective multicentre SVEAH study. Therapeutic Advances in Gastroenterology 2021; 14: 175628482110233 doi: 10.1177/17562848211023386
|
| 6 |
Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Yasuko Hirai, Kohei Asaeda, Takeshi Sugaya, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuki Minagawa,, Yuma Hotta, Makoto Tanaka, Ken Inoue, Kazuhiro Katada, Kazuhiro Kamada, Takeshi Ishikawa, Hiroaki Yasuda, Hideyuki Konishi, Mitsuo Kishimoto, Yuji Naito, Yoshito Itoh. Mucosal Addressin Cell Adhesion Molecule 1 Expression Reflects Mucosal Inflammation and Subsequent Relapse in Patients with Ulcerative Colitis. Journal of Crohn's and Colitis 2023; 17(5): 786 doi: 10.1093/ecco-jcc/jjac182
|
| 7 |
Piotr Eder, Maria Kłopocka, Halina Cichoż-Lach, Renata Talar-Wojnarowska, Maria Kopertowska-Majchrzak, Agata Michalak, Rafał Filip, Katarzyna Waszak, Kamila Stawczyk-Eder, Maria Janiak, Krzysztof Skrobot, Ariel Liebert, Hubert Zatorski, Anna Solarska-Półchłopek, Michał Krogulecki, Anna Pękała, Elżbieta Poniewierka, Izabela Smoła, Aleksandra Kaczka, Krzysztof Wojciechowski, Szymon Drygała, Edyta Zagórowicz. Real-world outcomes of 54-week vedolizumab therapy and response durability after treatment discontinuation in ulcerative colitis: results from a multicenter prospective POLONEZ study. Therapeutic Advances in Gastroenterology 2023; 16: 175628482311512 doi: 10.1177/17562848231151295
|
| 8 |
Ann-Lorie Gagnon, William Beauchesne, Laurence Tessier, Charles David, Djamal Berbiche, Alexandre Lavoie, Alban Michaud-Herbst, Karine Tremblay. Adalimumab, Infliximab, and Vedolizumab in Treatment of Ulcerative Colitis: A Long-Term Retrospective Study in a Tertiary Referral Center. Crohn's & Colitis 360 2021; 3(4) doi: 10.1093/crocol/otab049
|
| 9 |
Mohamed Attauabi, Gorm Roager Madsen, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease – a systematic review with meta-analysis. Digestive and Liver Disease 2022; 54(9): 1168 doi: 10.1016/j.dld.2021.11.014
|
| 10 |
Kengo Kanayama, Jun Kato, Wataru Shiratori, Ariki Nagashima, Yuki Ohta, Takashi Taida, Keiko Saito, Chihiro Goto, Satsuki Takahashi, Ryosuke Horio, Akane Kurosugi, Tsubasa Ishikawa, Tatsuya Kaneko, Naoki Akizue, Kenichiro Okimoto, Tomoaki Matsumura, Naoya Kato. Anti‐TNFα antibody versus non‐anti‐TNFα molecular agents for ulcerative colitis patients who failed initial anti‐TNFα therapy. Journal of Gastroenterology and Hepatology 2022; 37(6): 1083 doi: 10.1111/jgh.15826
|
| 11 |
Tessa Straatmijer, Vince B.C. Biemans, Marijn Visschedijk, Frank Hoentjen, Annemarie de Vries, Adriaan A. van Bodegraven, Alexander Bodelier, Nanne K.H. de Boer, Gerard Dijkstra, Noortje Festen, Carmen Horjus, Jeroen M. Jansen, Bindia Jharap, Wout Mares, Fiona D.M. van Schaik, Cyriel Ponsioen, Tessa Romkens, Nidhi Srivastava, Michael M.P. J.A. van der Voorn, Rachel West, Janneke van der Woude, Marije D.J. Wolvers, Marieke Pierik, Andrea E. van der Meulen-de Jong, Marjolijn Duijvestein, Malena Schlotter, Martine van Workum, Dirk de Jong, Willemijn van Dop, S. van der Marel, Hayat El Ghabzouri, Kamila Talhaoui, Bas Oldenburg, Nynke Boontje, Herma Fidder, Meike Hirdes, Rob H. Creemers, J. Hoekstra, Jael Smid, Zlatan Mujagic, Marthe François-Verweij, Toos Schakel- van den Berge, Jeroen Maljaars, Rosaline Theeuwen, Denise van den Berg, Suzanne Gerretsen, Xenia Yocarini, Geert D’Haens, Mark Lowenberg, Joep Grootjans, Krisztina Gecse, Gerd Bouma, Petra Waaijenberg, Bart Muskens. Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study. Clinical Gastroenterology and Hepatology 2023; 21(1): 182 doi: 10.1016/j.cgh.2022.04.038
|
| 12 |
Bincy Abraham, Kerri Glassner. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Current Opinion in Gastroenterology 2021; 37(4): 344 doi: 10.1097/MOG.0000000000000738
|
| 13 |
Fabio Salvatore Macaluso, Marco Ventimiglia, Ambrogio Orlando. Effectiveness and Safety of Vedolizumab in Inflammatory Bowel Disease: A Comprehensive Meta-analysis of Observational Studies. Journal of Crohn's and Colitis 2023; 17(8): 1217 doi: 10.1093/ecco-jcc/jjad043
|
| 14 |
Ashish R Srinivasan. Treat to target in Crohn’s disease: A practical guide for clinicians. World Journal of Gastroenterology 2024; 30(1): 50-69 doi: 10.3748/wjg.v30.i1.50
Abstract(152) |
Core Tip(157) |
Full Article(HTML)(2581)
|
Full Article with Cover (PDF)-2334K(105)
|
Full Article (Word)-573K(19)
|
Audio-403K(4)
|
Peer-Review Report-232K(17)
|
Answering Reviewers-60K(17)
|
Full Article (PDF)-922K(280)
|
Full Article (XML)-347K(18)
|
Times Cited (0)
|
Total Visits (3898)
|
Open
|
| 15 |
Mohamed Attauabi, Camilla Höglund, Janne Fassov, Kenneth Bo Pedersen, Heidi Bansholm Hansen, Signe Wildt, Michael Dam Jensen, Anders Neumann, Cecilie Lind, Henrik Albaek Jacobsen, Ana-Maria Popa, Jens Kjeldsen, Natalia Pedersen, Akbar Molazahi, Kent Haderslev, Claus Aalykke, Torben Knudsen, Wojciech Cebula, Pia Munkholm, Flemming Bendtsen, Jakob Benedict Seidelin, Johan Burisch. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scandinavian Journal of Gastroenterology 2021; 56(9): 1040 doi: 10.1080/00365521.2021.1946588
|
| 16 |
Adam Saleh, Usman Ansari, Shaadi Abughazaleh, Kerri Glassner, Bincy P Abraham. Biological Therapies for the Management of Enteric Disease: Considerations for the Clinician. Biologics: Targets and Therapy 2022; : 67 doi: 10.2147/BTT.S335697
|